TB-500 and Thymosin Beta-4: A Research Review

Thymosin beta-4 (Tβ4) is an abundant intracellular protein with a long research history in cell motility, wound repair and cardiac biology. "TB-500" is a commercial name attached to synthetic material derived from it, most often a short fragment rather than the full protein. Keeping the two apart is the single most important point when reading this literature: nearly all of the substantive data concern full-length Tβ4.

Origin and discovery

Tβ4 was characterised in the laboratory of Allan Goldstein, which had been fractionating calf thymus extracts in search of hormone-like immune factors. Low, Hu and Goldstein reported the complete amino acid sequence of bovine thymosin β4 in 1981. The thymic association turned out to be incidental: Tβ4 is expressed in almost all nucleated cells and is especially abundant in platelets, white blood cells and wound fluid.

A decade later, Safer, Elzinga and Nachmias (1991) showed that Tβ4 was identical to an actin-sequestering factor isolated from platelets. That finding reframed Tβ4 as a cytoskeletal regulator, and subsequent work extended its reported activities to cell migration, angiogenesis, inflammation and fibrosis.

The name TB-500 emerged later in commercial and veterinary settings. It is not an International Nonproprietary Name and does not refer to a single defined molecule across suppliers.

Structure and chemistry

Full-length Tβ4 is a 43-residue, N-terminally acetylated polypeptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES) with an average mass of roughly 4,963 Da. It is intrinsically disordered in solution and adopts structure only on binding actin.

Two regions receive particular attention:

• The central actin-binding motif, LKKTETQ (residues 17–23). This stretch is essential for G-actin binding and is the basis of most TB-500 fragment products, which are typically N-acetylated seven-residue peptides of about 889 Da.
• The N-terminal tetrapeptide Ac-SDKP. Released from Tβ4 by prolyl oligopeptidase, Ac-SDKP has been studied separately as an anti-fibrotic and haematopoietic regulator.

Because both a 7-residue fragment and the 43-residue protein are sold under the same name, the stated sequence and observed mass on a certificate of analysis are the only reliable way to know which molecule is present.

Mechanism studied

Tβ4 is the main G-actin-sequestering protein in many mammalian cells. By binding monomeric actin in a 1:1 complex, it buffers the pool available for filament assembly, which in turn affects cell shape, lamellipodia formation and motility.

Beyond this core role, studies have described:

• Survival and migration signalling. Bock-Marquette et al. (2004) reported that Tβ4 formed a complex with PINCH and integrin-linked kinase, activating Akt in cardiomyocytes.
• Angiogenesis. Tβ4 promoted endothelial cell migration and tube formation in vitro and vessel growth in several animal models.
• Progenitor activation. Smart et al. (2007) reported that Tβ4 mobilised epicardial progenitor cells and supported neovascularisation in adult mouse hearts.
• Inflammation. Reduced NF-κB activation and inflammatory cytokine expression have been reported in corneal and other models.

How an intracellular actin-binding protein exerts these effects from outside the cell is not fully resolved. Proposed explanations include cell-surface interactions, uptake and secretion pathways, and the activity of cleavage products such as Ac-SDKP.

Research landscape by model system

In vitro

Tβ4 increased migration of keratinocytes, endothelial cells and corneal epithelial cells in scratch and chamber assays. Fragment studies suggest the LKKTETQ region accounts for some of the migratory activity, but the fragment has been characterised far less than the full protein.

Animal models

• Dermal wounds. Malinda et al. (1999) reported faster re-epithelialisation and wound contraction in a rat full-thickness wound model, and later studies extended this to diabetic and aged rodents.
• Cardiac injury. In mouse coronary ligation models, Tβ4 was associated with improved cardiomyocyte survival, reduced scarring and preserved function (Bock-Marquette et al., 2004). Smart et al. (2011) reported that Tβ4 priming could induce new cardiomyocytes from epicardial progenitors, although the extent of this effect has been debated in later work.
• Eye and nervous system. Corneal epithelial wound models, and rodent models of stroke and traumatic brain injury, have also been examined.
• Veterinary and equine contexts. TB-500 has been detected in racing animals, prompting development of analytical detection methods by anti-doping laboratories.

Human trials

Clinical work has used full-length Tβ4, not the TB-500 fragment. A phase 1 study in healthy volunteers assessed safety and pharmacokinetics (Ruff et al., 2010). Tβ4 was then evaluated in phase 2 and phase 3 studies in dry eye disease and neurotrophic keratopathy, and in smaller studies in chronic wound populations. Results have been mixed, with some secondary endpoints favouring Tβ4 and several primary endpoints not met. No Tβ4 product has received regulatory approval.

Evidence quality and open questions

For full-length Tβ4, preclinical evidence is moderate, with independent replication across several laboratories and high-profile publications. Clinical evidence is limited to narrow indications and has not yet produced a confirmatory positive trial.

For the TB-500 fragment, evidence is very low. Open questions include:

1. Fragment versus protein. Which of Tβ4's activities, if any, are retained by a 7-residue fragment lacking the N-terminus and the C-terminal region?
2. Extracellular mechanism. The receptor or uptake pathway for extracellular Tβ4 remains undefined.
3. Cardiac progenitor findings. Lineage-tracing results have been difficult to reproduce consistently, and the size of any regenerative effect is uncertain.
4. Oncology. Tβ4 expression has been associated with migration and metastasis in some tumour models, so pro-migratory effects need careful context.

Regulatory and anti-doping status

Neither Tβ4 nor TB-500 is approved by the FDA or EMA. WADA lists "thymosin-β4 and its derivatives, e.g. TB-500" by name under section S2 (peptide hormones, growth factors, related substances and mimetics), so it is prohibited at all times in sport. Horse-racing authorities also prohibit it. Research vendors supply it only as laboratory reference material.

Summary table

Attribute	Full-length Tβ4	TB-500 fragment
Length	43 residues, N-acetylated	Usually 7 residues (Ac-LKKTETQ)
Approx. mass	~4,963 Da	~889 Da
Core activity	G-actin sequestration	Contains the actin-binding motif
Main model systems	Rodent dermal, cardiac, corneal and neurological models	Few dedicated studies
Human data	Phase 1–3 studies in ocular-surface and chronic-wound indications	None published
Evidence level	Moderate (preclinical); limited (clinical)	Very low
FDA / EMA	Not approved	Not approved
WADA	Prohibited, S2 (named)	Prohibited, S2 (named)

References

• Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA. 1981;78(2):1162–1166.
• Safer D, Elzinga M, Nachmias VT. Thymosin β4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029–4032.
• Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364–368.
• Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432:466–472.
• Smart N, Risebro CA, Melville AAD, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445:177–182.
• Smart N, Bollini S, Dubé KN, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474:640–644.
• Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223–229.
• Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51.
• World Anti-Doping Agency. Prohibited List (current edition). wada-ama.org.